

Electronic Supplementary Information (ESI)

An Iron Carbonyl Approach to the Influenza Neuraminidase Inhibitor Oseltamivir

Karen M. Bromfield,^a Henrik Gradén,^{a,b} Daniel Hagberg,^a Thomas Olsson^b and Nina Kann^{*a}

^a Organic Chemistry, Department of Chemical and Biological Engineering, Chalmers University of Technology, 41296 Göteborg, Sweden.

^b Medicinal Chemistry, AstraZeneca R&D Mölndal, 43183 Mölndal, Sweden.

Spectra for the Synthesis of Oseltamivir:

Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron ((±)- 2):	
¹ H NMR	S2
¹³ C NMR	S4
Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron Hexafluorophosphate ((-)- 3b):	
¹ H NMR	S5
¹³ C NMR	S6
Tricarbonyl[1-carboethoxy-5-[(1 <i>R</i> ,2 <i>S</i>)- <i>trans</i> -2-phenylcyclohexyl]oxy]cyclohexa-1,3-diene]iron ((-)- 4b):	
¹ H NMR [*]	S7
¹³ C NMR	S8
Tricarbonyl[5-(<i>tert</i> -butoxycarbonylamino)-1-carboethoxycyclohexa-1,3-diene]iron ((-)- 5S)- 5b):	
¹ H NMR	S9
¹³ C NMR	S10
Ethyl 5-(<i>tert</i> -Butoxycarbonylamino)-cyclohexa-1,3-diene-1-carboxylate ((-)- 5S)- 6b):	
Crude ¹ H NMR	S11
Ethyl 5-(<i>tert</i> -Butoxycarbonylamino)-3,4-epoxy-cyclohexa-1-ene-1-carboxylate ((+)- 3R,4S,5S)- 7):	
Crude ¹ H NMR	S12
Crude ¹³ C NMR	S13
Ethyl 3-Azido-5-(<i>tert</i> -butoxycarbonylamino)-4-hydroxy-cyclohexa-1-ene-1-carboxylate ((±)- 8): [†]	
¹ H NMR	S14
¹³ C NMR	S15
Ethyl 3-Azido-5-(<i>tert</i> -butoxycarbonylamino)-4-[(methylsulfonyl)oxy]-cyclohexa-1-ene-1-carboxylate ((+)- 3S,4S,5S)- 9): [*]	
¹ H NMR	S16
¹³ C NMR	S17
Ethyl 3-(<i>N</i> -Acetylaziridinyl)-5-(<i>tert</i> -butoxycarbonylamino)-cyclohexa-1-ene-1-carboxylate ((±)- 10): [‡]	
¹ H NMR	S18
¹³ C NMR	S19
Ethyl 4-Acetylamino-5-(<i>tert</i> -butoxycarbonylamino)-3-(1-ethylpropoxy)-cyclohexa-1-ene-1-carboxylate ((-)- 3R,4R,5S)- 11):	
¹ H NMR [§]	S20
¹³ C NMR	S21

Also available is a separate ESI file containing all experimental procedures.


^{*} Residual solvent was removed by high vacuum before further analysis

[†] The shown racemic sample was purified for characterisation, where as samples of the desired enantiomer were used crude in the next step and therefore not characterized.



[‡] The shown racemic sample was purified for characterisation, where as samples of the desired enantiomer were of lower purity and therefore not characterized fully.

[§] The signal at 1.8 ppm disappeared with high vacuum and was therefore attributed to H-bonded H₂O in this sample.


Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron ((±)-2): ^1H NMR (400 MHz, CDCl_3)





Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron ((±)-2): ¹H NMR (400 MHz, CDCl₃).....cont





Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron ((±)-2) ¹³C NMR (100 MHz, CDCl₃)




Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron hexafluorophosphate ((-)-3b): ^1H NMR (400 MHz, CD_3OD)




Tricarbonyl(1-carboethoxycyclohexa-1,3-dienyl)iron hexafluorophosphate ((-)-3b): ^{13}C NMR (100 MHz, CD_3CN)




Tricarbonyl[1-carboethoxy-5-[[*(1R,2S)*-*trans*-2-phenylcyclohexyl]oxy]cyclohexa-1,3-diene]iron ((-)-4b): ^1H NMR (400 MHz, CDCl_3) *




Tricarbonyl[1-carboethoxy-5-[[*(1R,2S)*-*trans*-2-phenylcyclohexyl]oxy]cyclohexa-1,3-diene]iron ((-)-4b): ^{13}C NMR (100 MHz, CDCl_3)




Tricarbonyl[5-(*tert*-butoxycarbonylamino)-1-carboethoxycyclohexa-1,3-diene]iron ((-)-(5*S*)-5b): ^1H NMR (400 MHz, CDCl_3)




Tricarbonyl[5-(*tert*-butoxycarbonylamino)-1-carboethoxycyclohexa-1,3-diene]iron ((-)-(5*S*)-5b): ^{13}C NMR (100 MHz, CDCl_3)




Ethyl 5-(*tert*-Butoxycarbonylamino)-cyclohexa-1,3-diene-1-carboxylate ((-)-(5*S*)-6b): Crude ^1H NMR (400 MHz, CDCl_3)





Ethyl 5-(*tert*-Butoxycarbonylamino)-3,4-epoxy-cyclohexa-1-ene-1-carboxylate ((+)-(3*R*,4*S*,5*S*)-7): Crude ¹H NMR (400 MHz, CDCl₃)





Ethyl 5-(*tert*-Butoxycarbonylamino)-3,4-epoxy-cyclohexa-1-ene-1-carboxylate ((+)-(3*R*,4*S*,5*S*)-7): Crude ^{13}C NMR (100 MHz, CDCl_3)




Ethyl 3-Azido-5-(*tert*-butoxycarbonylamino)-4-hydroxy-cyclohexa-1-ene-1-carboxylate ((±)-8):[†] ¹H NMR (400 MHz, CDCl₃)




Ethyl 3-Azido-5-(*tert*-butoxycarbonylamino)-4-hydroxy-cyclohexa-1-ene-1-carboxylate ((±)-8):[†] ¹³C NMR (100 MHz, CDCl₃)




Ethyl 3-Azido-5-(*tert*-butoxycarbonylamino)-4-[(methylsulfonyl)oxy]-cyclohexa-1-ene-1-carboxylate ((+)-(3*S*,4*S*,5*S*)-9): ¹H NMR (400 MHz, CDCl₃)*





Ethyl 3-Azido-5-(*tert*-butoxycarbonylamino)-4-[(methylsulfonyl)oxy]-cyclohexa-1-ene-1-carboxylate ((+)-(3*S*,4*S*,5*S*)-9): ^{13}C NMR (100 MHz, CDCl_3)



Ethyl 3-(*N*-Acetylaziridinyl)-5-(*tert*-butoxycarbonylamino)-cyclohexa-1-ene-1-carboxylate ((±)-10):[‡] ¹H NMR (400 MHz, CDCl₃)




Ethyl 3-(*N*-Acetylaziridiny)-5-(*tert*-butoxycarbonylamino)-cyclohexa-1-ene-1-carboxylate ((±)-10):[‡] ¹³H NMR (100 MHz, CDCl₃)



Ethyl 4-Acetylamino-5-(*tert*-butoxycarbonylamino)-3-(1-ethylpropoxy)-cyclohexa-1-ene-1-carboxylate ((-)-(3*R*,4*R*,5*S*)-11):

¹H NMR (400 MHz, CDCl₃)[§]



Ethyl 4-Acetylamino-5-(*tert*-butoxycarbonylamino)-3-(1-ethylpropoxy)-cyclohexa-1-ene-1-carboxylate ((-)-(3*R*,4*R*,5*S*)-11):

¹³C NMR (100 MHz, CDCl₃)

